共 50 条
- [42] Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation studyJOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (07): : 723 - 736Chatterjee, ADigumarti, RMamidi, RNVSKatneni, KUpreti, VVSurath, ASrinivas, MLUppalapoti, SJiwatani, SESubramaniam, SSrinivas, NR
- [43] A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BC3402 in advanced solid malignanciesCANCER RESEARCH, 2024, 84 (07)Wu, Yi-LongChen, HuajunWang, ShengZhang, RuiTang, En-TzuZhang, WeiweiGu, KaicunWang, YiweiHei, Yongjiang
- [44] Results of Phase I/ II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with FLT3 or CBL MutationsBLOOD, 2023, 142Montalban-Bravo, GuillermoJabbour, EliasChien, Kelly S.Hammond, Danielle E.Short, Nicholas J.Ravandi, FarhadKonopleva, Marina Y.Borthakur, GautamDaver, NavalKanagal-Shamanna, RashmiQiao, WeiHuang, XuelinSchneider, HeatherMeyer, Meghan AnneKantarjian, Hagop M.Garcia-Manero, Guillermo
- [45] Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD StatusBLOOD, 2012, 120 (21)Cortes, Jorge E.Kantarjian, Hagop M.Foran, James M.Ghirdaladze, DarejanZodelava, MamiaBorthakur, GautamGammon, GuyTrone, DeniseArmstrong, Robert C.James, JoyceLevis, Mark J.
- [46] Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label StudyCLINICAL THERAPEUTICS, 2022, 44 (09) : 1237 - 1247Sohn, WinnieWinkle, PeterNeutel, JoelWu, YouJabari, FreemanTerrio, CaitlinVarrieur, TracyWang, JingyingHellawell, Jennifer
- [47] A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB InhibitorJOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (12): : 1557 - 1565Dennie, JustinVandell, Alexander G.Inoue, SatoshiGajee, RoohiPav, JosephZhang, GeorgeZamora, CynthiaMasuda, NobuhisaUchiyama, MinoruYamada, MakikoSenaldi, Giorgio
- [48] Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL MutationsBLOOD, 2021, 138Abuasab, TareqJabbour, Elias J.Short, Nicholas J.Konopleva, MarinaChien, Kelly S.Mohamed, Shehab FareedDaver, NavalKanagal-Shamanna, RashmiKantarjian, HagopGarcia-Manero, GuillermoMontalban-Bravo, Guillermo
- [49] Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical TrialFRONTIERS IN PHARMACOLOGY, 2021, 12Joshi, DeepaJamadarkhana, PrashantKumbhare, SuchitSingh, AmarinderKotecha, JigneshBunger, DeepakShiwalkar, AjayMohanan, AnookhDutt, Chaitanya
- [50] Results of a Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101: Preliminary Safety and Activity in Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma PatientsBLOOD, 2016, 128 (22)Eyre, Toby A.Collins, Graham P.Gupta, AvinashSheikh, SemiraWoodcock, VictoriaWhittaker, JohnWang, Lai MunSoilleux, ElizabethTysoe, FinnCousins, RichardLa Thangue, NickKerr, DavidMiddleton, Mark R.